<DOC>
	<DOCNO>NCT03030508</DOCNO>
	<brief_summary>At present , chemotherapy widely use adjuvant treatment colorectal cancer patient surgery . Capecitabine one main chemotherapeutic drug . But effect good enough , adverse reaction serious , individual difference significant . The present study show problem related difference exposure capecitabine metabolite different patient . The genetic biomarkers capecitabine include DRD , MTHFR TYMS . Mutations gene directly affect expression metabolic enzymes involved capecitabine control concentration capecitabine metabolite . However , marker obtain clinical trial United States , role predict effectiveness safety capecitabine metabolite validate Chinese cancer patients.The study base case study patient colorectal cancer China , capecitabine primary postoperative chemotherapy regimen verify whether available biomarkers use predict effectiveness safety capecitabine . To clarify effect capecitabine endogenous metabolite , study mechanism effect , discover new biomarkers .</brief_summary>
	<brief_title>Discovery Validate Multi-genetic Biomarkers Capecitabine Chinese Colorectal Patients</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1. 18 year old ; 2. patient colon cancer diagnose biopsy ( regardless cancer stage ) ; 3. receive postoperative contain capecitabine chemotherapy ; 4. volunteer participate experiment 1. pregnant lactate woman ; 2. patient hypersensitivity fluorouracil severe metabolic failure ; 3. patient severe infection ; 4. patient cancer colorectal cancer within first five year colorectal cancer surgery ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>biomarks</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>capecitabine</keyword>
	<keyword>gene polymorphism</keyword>
</DOC>